Diagnostic and clinical significance of cell free DNA levels in patients with chronic heart failure

Abstract

BACKGROUND: Chronic heart failure CHF remains one of the main causes of disability in patients with cardiovascular diseases. Leading to the development of persistent dysfunctions of the entire body, CHF significantly reduces the quality of life and worsens the patient’s prognosis. Therefore, it is so important to promptly identify the disease and carry out optimal therapy, which will delay the onset of irreversible consequences.

AIM: Analysis of cell free DNA level of in the blood plasma in patients with chronic heart failure and identification of differences in the studied indicator depending on the clinical characteristics of the patient.

MATERIALS AND METHODS: The study included 67 patients diagnosed with chronic heart failure and 23 healthy volunteers who were in satisfactory health, who made up the comparison group. All subjects underwent a gender and age assessment, analysis of risk factors, anthropometric indicators with calculation of body mass index. In patients with CHF, clinical and biochemical blood tests were performed to determine NT-proBNP, lipid profile, glucose and creatinine; In addition, an instrumental examination was performed, including electrocardiography, echocardiography, fundus examination, ultrasound examination of the abdominal organs, chest radiography, and a 6-minute walk test to assess the functional class. The level of cell free DNA was determined according to the method of P.P. Laktionova, S.N. Tamkovich, E.Yu. Rykova (2005). In the study group of patients, the causes of CHF development were analyzed, and the presence of a history of myocardial infarction and its duration were separately taken into account.

RESULTS: The study established the average level of cell free DNA for patients with CHF (273.5±25.26 ng/ml) and in the comparison group (53.7±3.5 ng/ml), which is a statistically significant difference (p=0,00). Analysis of the causes of chronic heart failure revealed a combination of coronary heart disease and arterial hypertension as the main etiological factor; the number of patients in the study group was 58%. A decrease in exercise tolerance, revealed during the 6 minute walk test, is accompanied by an increase in the level of cell free DNA in the blood, with a progressive increase in concentration from functional class I (141.9±26.3 ng/ml) to functional class III (447.7±51.7 ng/ml). Among patients suffering from coronary artery disease, a history of myocardial infarction leads to an increase in the level of free circulating DNA by almost 2 times compared with patients with a stable course of coronary heart disease. Also, the level of free circulating DNA depends on the duration of acute myocardial infarction, demonstrating a significant difference between the early (440.8±87.6 ng/ml) and late recovery period (225.5±46.5 ng/ml).

CONCLUSION: Significant differences in cell free DNA levels were revealed between the group of patients with CHF and the control group, which allows us to consider this marker as a potential diagnostic criterion for CHF

Keywords

cell free DNA / chronic heart failure / biomarkers / myocardial infarction / cardiovascular disease

References

[1] 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ). doi: 10.15829/1560-4071-2020-4083

[2] Хроническая сердечная недостаточность. Клинические рекомендации 2020 // Российский кардиологический журнал. 2020. Т. 25, № 11. С. 4083. doi: 10.15829/1560-4071-2020-4083

[3] Ageev FT, Arutyunov GP, Belenkov YuN, et al. Chronic heart failure. Moscow: GEOTAR-Media; 2010. 336 p. (in Russ).

[4] Агеев Ф.Т., Арутюнов Г.П., Беленков Ю.Н., и др. Хроническая сердечная недостаточность. Москва: ГЭОТАР-Медиа, 2010. 336 с.

[5] Shah SJ. BNP: Biomarker Not Perfect in heart failure with preserved ejection fraction. European Heart Journal. 2022;43(20):1952–1954. doi: 10.1093/eurheartj/ehac121

[6] Shah S.J. BNP: Biomarker Not Perfect in heart failure with preserved ejection fraction // European Heart Journal. 2022. Vol. 43, № 20. P. 1952–1954. doi: 10.1093/eurheartj/ehac121

[7] Yancy CW, Jessup M, Bozkurt B, et al. Focused Update of the 2013 AC-CF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):137–161. doi: 10.1161/CIR.0000000000000509

[8] Yancy C.W., Jessup M., Bozkurt B., et al. Focused Update of the 2013 AC-CF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America // Circulation. 2017. Vol. 136, № 6. P. 137–161. doi: 10.1161/CIR.0000000000000509

[9] Trofimova EA, Kireeva VV, Usoltsev YuK, et al. Circulating free DNA in hypertensive patients with high cardiovascular risk. Russian Journal of Cardiology. 2022;27(4):4709. (In Russ). doi: 10.15829/1560-4071-2022-4709

[10] Трофимова Е.А., Киреева В.В., Усольцев Ю.К., и др. Свободно циркулирующая ДНК у больных артериальной гипертензией с высоким сердечно-сосудистым риском // Российский кардиологический журнал. 2022. Т. 27, № 4. С. 4709. doi: 10.15829/1560-4071-2022-4709

[11] Polina IA, Ilatovskaya DV, DeLeon-Pennell KY. Cell free DNA as a diagnostic and prognostic marker for cardiovascular diseases. Clin Chim Acta. 2020;503:145–150. doi: 10.1016/j.cca.2020.01.013

[12] Polina I.A., Ilatovskaya D.V., DeLeon-Pennell K.Y. Cell free DNA as a diagnostic and prognostic marker for cardiovascular diseases // Clin Chim Acta. 2020. Vol. 503. P. 145–150. doi: 10.1016/j.cca.2020.01.013

[13] Zemmour H, Planer D, Magenheim J, et al. Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA. Nat Commun. 2018;9(1):1443. doi: 10.1038/s41467-018-03961-y

[14] Zemmour H., Planer D., Magenheim J., et al. Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA // Nat Commun. 2018. Vol. 9, № 1. P. 1443. doi: 10.1038/s41467-018-03961-y

[15] Yokokawa T, Misaka T, Kimishima Y, et al. Clinical significance of circulating cardiomyocyte-specific cell-free DNA in patients with heart failure: a proof-of-concept study. Can J Cardiol. 2020;36(6):931–935. doi: 10.1016/j.cjca.2019.10.016

[16] Yokokawa T., Misaka T., Kimishima Y., et al. Clinical Significance of Circulating Cardiomyocyte-Specific Cell-Free DNA in Patients with Heart Failure: A Proof-of-Concept Study // Can J Cardiol. 2020. Vol. 36, № 6. P. 931–935. doi: 10.1016/j.cjca.2019.10.016

[17] Karper JC, Ewing MM, Habets KL, et al. Blocking toll-like receptors 7 and 9 reduces postinterventional remodeling via reduced macrophage activation, foam cell formation, and migration. Arterioscler Thromb Vasc Biol. 2012;32(8):72–80. doi: 10.1161/ATVBAHA.112.249391

[18] Karper J.C., Ewing M.M., Habets K.L., et al. Blocking toll-like receptors 7 and 9 reduces postinterventional remodeling via reduced macrophage activation, foam cell formation, and migration // Arterioscler Thromb Vasc Biol. 2012. Vol. 32, № 8. P. 72–80. doi: 10.1161/ATVBAHA.112.249391

[19] Ingle L, Cleland JG, Clark AL. The long-term prognostic significance of 6-minute walk-test distance in patients with chronic heart failure. Biomed Res Int. 2014;2014:505969. doi: 10.1155/2014/505969

[20] Ingle L., Cleland J.G., Clark A.L. The long-term prognostic significance of 6-minute walk-test distance in patients with chronic heart failure // Biomed Res Int. 2014. Vol. 2014. Р. 505969. doi: 10.1155/2014/505969

[21] Patent RUS № 2232768/ 07.20.2004. Byul. № 20. A method for isolating the DNA of microorganisms. Laktionov PP, Tamkovich SN, Simonov PA, et al. Available from: https://patents.google.com/patent/RU2232768C2/ru

[22] Патент РФ на изобретение № 2232768/ 20.07.2004. Бюл. № 20. Лактионов П.П., Тамкович С.Н., Симонов П.А., и др. Способ выделения ДНК микроорганизмов. Режим доступа: https://patents.google.com/patent/RU2232768C2/ru

[23] Teo YV, Capri M, Morsiani C, et al. Cell-free DNA as a biomarker of aging. Aging Cell. 2019;18(1):e12890. doi: 10.1111/acel.12890

[24] Teo Y.V., Capri M., Morsiani C., et al. Cell-free DNA as a biomarker of aging // Aging Cell. 2019. Vol. 18, № 1. Р. e12890. doi: 10.1111/acel.12890

[25] Wu B, Ni H, Li J, et al. The Impact of Circulating Mitochondrial DNA on Cardiomyocyte Apoptosis and Myocardial Injury After TLR4 Activation in Experimental Autoimmune Myocarditis. Cell Physiol Biochem. 2017;42(2):713–728. doi: 10.1159/000477889

[26] Wu B., Ni H., Li J., et al. The Impact of Circulating Mitochondrial DNA on Cardiomyocyte Apoptosis and Myocardial Injury After TLR4 Activation in Experimental Autoimmune Myocarditis // Cell Physiol Biochem. 2017. Vol. 42, № 2. P. 713–728. doi: 10.1159/000477889

[27] Aronov DM. Cardiac rehabilitation and secondary prevention. Moscow: GEOTAR-Media; 2021. 337 p. (in Russ).

[28] Аронов Д.М. Кардиореабилитация и вторичная профилактика. Москва: ГЭОТАР-Медиа, 2021. 337 с.

[29] Fomin IV, Belenkov YuN, Mareev VYu. The prevalence of chronic heart failure in the European part of the Russian Federation (part 1) — EPOCHA-CHF data. Journal of Heart Failure. 2006;7,1(35):4–7. (in Russ). doi: 10.15829/1560-4071-2016-8-7-13

[30] Фомин И.В., Беленков Ю.Н., Мареев В.Ю., и др. Распространённость хронической сердечной недостаточности в европейской части Российской Федерации (часть 1) — данные ЭПОХА-ХСН // Сердечная недостаточность. 2006. Т. 7, № 1(35). С. 4–7. doi: 10.15829/1560-4071-2016-8-7-13

[31] Chaulin AM, Abashina OE, Duplyakov DV. Highly sensitive cardiac troponins (hs-Tn): methods of determination and main analytical characteristics. Cardiovascular Therapy and Prevention. 2021;20(2):2590. (in Russ). doi: 10.15829/1728-8800-2021-2590

[32] Чаулин А.М., Абашина О.Е., Дупляков Д.В. Высокочувствительные сердечные тропонины (hs-Tn): методы определения и основные аналитические характеристики // Кардиоваскулярная терапия и профилактика. 2021. Т. 20, № 2. С. 2590. doi: 10.15829/1728-8800-2021-2590

[33] Shimony A, Zahger D, Gilutz H, et al. Cell free DNA detected by a novel method in acute ST-elevation myocardial infarction patients. Acute Card Care. 2010;12(3):109–111. doi: 10.3109/17482941.2010.513732

[34] Shimony A., Zahger D., Gilutz H., et al. Cell free DNA detected by a novel method in acute ST-elevation myocardial infarction patients // Acute Card Care. 2010. Vol. 12, № 3. P. 109–111. doi: 10.3109/17482941.2010.513732

RIGHTS & PERMISSIONS

Eco-Vector